Tuberculosis and HIV co-infection—focus on the Asia-Pacific region  by Trinh, Q.M. et al.
International Journal of Infectious Diseases 32 (2015) 170–178Review
Tuberculosis and HIV co-infection—focus on the Asia-Paciﬁc region
Q.M. Trinh a,b,c,*, H.L. Nguyen d, V.N. Nguyen e, T.V.A. Nguyen c,
V. Sintchenko a,b, B.J. Marais a
aMarie Bashir Institute for Infectious Diseases and Biosecurity (MBI), The University of Sydney, Sydney, Australia
bCentre for Infectious Disease and Microbiology – Public Health, ICPMR, Westmead Hospital, Sydney, Australia
c Tuberculosis Laboratory, Vietnam National Institute of Hygiene and Epidemiology, Hanoi, Vietnam
dVietnam Administration of HIV/AIDS Control, Hanoi, Vietnam
eVietnam National Lung Hospital, Hanoi, Vietnam
A R T I C L E I N F O
Article history:
Received 12 November 2014
Accepted 24 November 2014
Corresponding Editor:
Jørgen Eskild Petersen, Aarhus, Denmark
Keywords:
Tuberculosis
HIV
Co-infection
S U M M A R Y
Tuberculosis (TB) is the leading opportunistic disease and cause of death in patients with HIV infection.
In 2013 there were 1.1 million new TB/HIV co-infected cases globally, accounting for 12% of incident TB
cases and 360 000 deaths. The Asia-Paciﬁc region, which contributes more than a half of all TB cases
worldwide, traditionally reports low TB/HIV co-infection rates. However, routine testing of TB patients
for HIV infection is not universally implemented and the estimated prevalence of HIV in new TB cases
increased to 6.3% in 2013. Although HIV infection rates have not seen the rapid rise observed in Sub-
Saharan Africa, indications are that rates are increasing among speciﬁc high-risk groups. This paper
reviews the risks of TB exposure and progression to disease, including the risk of TB recurrence, in this
vulnerable population. There is urgency to scale up interventions such as intensiﬁed TB case-ﬁnding,
isoniazid preventive therapy, and TB infection control, as well as HIV testing and improved access to
antiretroviral treatment. Increased awareness and concerted action is required to reduce TB/HIV co-
infection rates in the Asia-Paciﬁc region and to improve the outcomes of people living with HIV.
 2014 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/3.0/).
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In recent years, expectations of a global epidemiological
transition, with a shift in emphasis from acute infections in
childhood to chronic diseases in later life, has provided the central
narrative of global health.1 However, despite progress towards the
World Health Organization (WHO) Millennium Development
Goals (MDGs) associated with major infectious diseases, low-
and middle-income countries still suffer an enormous infectious
disease burden. In fact, most now face a double burden of disease
with rising rates of non-communicable diseases, driven by
demographic and lifestyle changes, together with an unresolved
infectious diseases agenda.2
Among infectious diseases, both tuberculosis (TB) and HIV/AIDS
represent global public health emergencies. Their mutually
detrimental effect on the individual patient and at the population
level is most evident in Sub-Saharan Africa.3 The impact of TB/HIV
co-infection in the Asia-Paciﬁc region (which includes WHO-
deﬁned South East Asia and Western Paciﬁc regions) is poorly* Corresponding author. Tel.: +84 983110183.
E-mail address: qtri6675@uni.sydney.edu.au (Q.M. Trinh).
http://dx.doi.org/10.1016/j.ijid.2014.11.023
1201-9712/ 2014 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).understood; in this region, HIV infection is less common and the
infrastructure to deal with co-infected patients less well devel-
oped. This review examines the disease burdens associated with
TB, HIV/AIDS, and TB/HIV co-infection in the Asia-Paciﬁc region,
reﬂects on key management challenges, and explores the relative
contribution of relapse and re-infection to TB recurrence in
HIV-infected patients.
2. Tuberculosis
According to the WHO, an estimated 9.0 million people
developed TB in 2013, with 1.5 million deaths attributed to TB,
excluding deaths among HIV-infected patients.3 More than 80% of
cases occurred in 22 high burden countries. Nine of the 22 (41%)
high burden countries are located in the Asia-Paciﬁc region
(Figure 1a).
An estimated ﬁve million new TB cases occurred in the Asia-
Paciﬁc region during 2013, representing approximately 55% of the
global TB disease burden. According to the estimated number
of incident cases India ranks ﬁrst, China second, Indonesia
ﬁfth, Bangladesh seventh, Philippines eighth, Myanmar eleventh,
Vietnam thirteenth, Thailand eighteenth, and Cambodiaciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
Figure 1. Global disease burden associated with TB and HIV.
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and China for 19.6% (980,000 cases) of the Asia-Paciﬁc TB case load.
Indonesia, Bangladesh, and Philippines ranked third, fourth, and
ﬁfth in the region, accounting for 9.2% (460 000 cases), 7% (350 000
cases), and 5.2% (260 000 cases) of cases, respectively.4 Major gains
in TB epidemic control reported for the Asia-Paciﬁc region have
been driven mainly by socio-economic improvements in China,
and to some degree in India.5 Countries such as Myanmar,
Democratic People’s Republic of Korea, East Timor, and Papua New
Guinea represent TB hotspots within the Asia-Paciﬁc region, with
TB incidence rates exceeding 300/100 000 population. However,
these countries have reduced visibility due to uncertain dataquality and relatively small population sizes, which limit their
inﬂuence on aggregated regional and global ﬁgures.
Similar to other parts of the world, TB incidence rates in the
Asia-Paciﬁc region are broadly associated with poverty and limited
public health infrastructure.6 Speciﬁc factors that contribute to
TB vulnerability at the population level include rising rates of
diabetes on the one hand, with persistent high rates of malnutri-
tion on the other.7 Diabetes is a growing concern throughout the
region, but is especially prevalent in Paciﬁc Island countries
where its detrimental health impacts are most pronounced.8
Cigarette smoking and air pollution, both indoor and outdoor, pose
major threats to lung health.9 They also increase the TB disease risk
Table 1
Prevalence of HIV co-infection among incident TB cases (2013); comparing TB
endemic countries in Africa and the Asia-Paciﬁca
Country HIV prevalence
(age 15–49 years)14
TB incidence
(per 100 000
population)3
HIV prevalence
in incident
TB cases3
HIV prevalence 10%
Swaziland 27.4% 1382 74.0%
Zimbabwe 15.0% 552 72.0%
Zambia 12.5% 410 62.0%
Botswana 21.9% 414 61.0%
South Africa 19.1% 860 61.0%
Mozambique 10.8% 552 57.0%
HIV prevalence 1–9%
Uganda 7.4% 166 52.0%
Kenya 6.0% 268 41.0%
UR Tanzania 5.0% 164 37.0%
Nigeria 3.2% 338 25.0%
Thailand 1.1% 119 15.0%
Ethiopia 1.2% 224 11.0%
DR Congo 1.1% 326 7.5%
HIV prevalence <1%
Papua New Guinea 0.7% 347 14.0%
Myanmar 0.6% 373 8.8%
Vietnam 0.4% 144 7.2%
India 0.3% 171 5.7%
Cambodia 0.7% 400 3.9%
Indonesiab 0.5% 183 3.2%
Bangladesh <0.1% 224 0.12%
Philippines <0.1% 292 0.11%
a Endemic countries have a TB incidence rate 100/100 000 population; Asia-
Paciﬁc countries are in bold type. Adapted from the World Health Organization
Global Tuberculosis Report 2014.3
b Only 2.3% of TB cases were tested for HIV-infection in Indonesia.3
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Cigarette smoking rates are on the rise in the Asia-Paciﬁc region,
with little political will to reverse this trend.10 Rising rates of
outdoor air pollution linked to rapid economic growth and
urbanization are evident throughout the region, while the use of
inefﬁcient wood- and coal-ﬁred stoves for indoor cooking and
heating remain widespread.
A particular concern for the region is its vast and mobile
population, which may facilitate TB transmission, particularly in
settings where vulnerable people congregate.11 Large movements
of migrant workers between different districts and countries,
complicates timely TB diagnosis and treatment adherence. Prisons
also act as epidemic ampliﬁers in some TB endemic areas and the
same may apply to hospitals and clinics with poor infection control
practices.12
3. HIV/AIDS
HIV infection is heavily concentrated in Sub-Saharan Africa
(Figure 1b),13,14 where women suffer high disease rates due to
predominant heterosexual transmission. In general, HIV infec-
tion rates among antenatal attendees appear to be low in the
Asia-Paciﬁc region, but the actual HIV/AIDS burden remains
poorly quantiﬁed as universal testing is rarely implemented.
Emerging evidence suggests that HIV infection rates are on the
rise among high-risk groups in Vietnam, including intravenous
drug users, female sex workers, and men who have sex with
men.15 In addition there is potential for spread among sexually
active parts of the population who may not perceive themselves
to be at high risk, as illustrated by increasing rates of other
sexually transmitted infections such as syphilis, chlamydia, and
gonorrhea.16,17
4. TB/HIV co-infection
TB and HIV/AIDS display a lethal bidirectional interaction, with
major epidemic overlap (Figure 1a and b). People living with HIV
are almost 30 times more likely than HIV-uninfected people to
develop TB, and the chronic immune stimulation resulting from
active TB accelerates HIV/AIDS disease progression.18–20 There
were 360 000 TB-related deaths reported in people living with HIV
during 2013.3
Of all TB cases identiﬁed in 2013, 1.1 million (12%) were co-
infected with HIV. Sub-Saharan Africa, where the explosive spread
of the HIV epidemic fuelled a nearly ﬁve-fold increase in TB
notiﬁcation rates between 1990 and 2005,21,22 accounted for 75%
of TB/HIV co-infected patients (Figure 1c).3 The WHO ﬁrst
published policy documents on collaborative TB/HIV activities in
2004,23 followed by updates in 200824 and 2012.25 It outlined a
comprehensive strategy for better integrated TB/HIV services with
provider-initiated bidirectional active case ﬁnding that links TB
patients who are HIV-infected to optimal HIV care, and HIV-
infected patients with TB to early effective TB treatment. It
emphasized the need for early initiation of antiretroviral therapy
(ART), improved infection control practices, and the use of
isoniazid preventive therapy (IPT).
HIV testing is recommended for all patients with TB,23 with an
aspirational target of 100% compliance by 2015.26 Progress
outside Sub-Saharan Africa has been slow,27 particularly in the
Middle-East and Asia-Paciﬁc regions, with less than half of all TB
cases tested for HIV in 2013. HIV test coverage among TB patients
in Asia is less than 43%, but testing rates are highly variable,
ranging from 1.1% of newly diagnosed TB patients in Bangladesh
to 100% in Brunei and Bhutan.28 Recognized barriers to HIV testing
include the absence of national policy guidance, low uptake by
health care workers if proposed strategies are consideredunfeasible or not linked to functional HIV treatment services, a
shortage of HIV testing kits, inadequate supervision by both TB
and HIV programmes,29 and concerns about stigmatization. In
Africa, the perception of TB as a disease of the poor and ‘dirty’, low
conﬁdence in patient conﬁdentiality, and anticipated HIV-related
stigma undermines optimal care-seeking behaviour.30 In Asia,
HIV infection is intricately linked to drug abuse, previous
imprisonment, and being a sex worker, which acts as a major
barrier to routine testing and the provision of optimal care, due to
preconceived negative perceptions by patients and health care
workers.31
4.1. The Asia-Paciﬁc region
TB/HIV co-infection has not been considered a major driver of
the TB epidemic in the Asia-Paciﬁc region, although HIV
infection rates are high among certain groups. Up to 2011,
the estimated prevalence of TB/HIV co-infection was low at
17.2% in Asian countries compared with other regions such as
Africa, Europe, and Latin America.32 Data on HIV infection rates
among TB patients are unreliable since patients are infrequently
tested; a minority of countries in the Asia-Paciﬁc region tested
more than two-thirds of TB patients for HIV infection in 2013.3
The reliability of reported ﬁgures is hampered by poor
monitoring systems and limited collaboration between HIV
and TB control programmes.
Table 1 provides an overview of selected TB endemic
countries (TB incidence rate 100/100 000 population) in Africa
and Asia, categorized according to reported TB/HIV co-infection
rates. It is notable that TB endemic countries in Asia report
TB/HIV co-infection rates below 10% of notiﬁed TB cases (except
Thailand and Papua New Guinea); this is in stark contrast to
countries in Sub-Saharan Africa where co-infection rates
generally exceed 50%, reaching up to a maximum of 74% in
Swaziland.3,28 Among other Asia-Paciﬁc countries only Thailand
Table 2
TB risk and disease characteristics associated with different levels of HIV-induced
immune compromise
CD4 count,
cells/ml
TB risk and disease characteristics
500 Increased TB risk irrespective of CD4 count, but appreciably
lower risk compared to patients with a CD4 count <500 cells/ml
<500 WHO recommendation for ART initiation36
350–499 Mostly still typical upper zone inﬁltrates with/without
cavitation36
Increased atypical TB features37
Increased bacterial pneumonia (also super-infection with TB)36
Tuberculin skin test more likely to be false-negative37
200–349 As above (more pronounced)
100–199 Cavitation and positive sputum smear microscopy less common
Middle and lower lung zone inﬁltrates, intra-thoracic lymph
node enlargement and miliary pattern more common on chest
radiograph36
Extra-pulmonary disease more common37
<100 As above (even higher rates of disseminated and/or
extrapulmonary TB)50
TB-IRIS (unmasking and paradoxical)38
Recommendation to use combination of Xpert MTB/RIF (on
sputum) and Determine TB-LAM assay (on urine) as TB
screening test47
WHO, World Health Organization; ART, antiretroviral therapy; IRIS, immune
reconstitution inﬂammatory syndrome.
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(7.2%), and India (5.7%) exceed TB/HIV co-infection rates of 5%.3
In general, HIV infection rates have not seen the rapid rises
observed in Africa and the number of incident TB/HIV co-
infection cases has remained fairly constant in recent years, with
an estimated 193 000 co-infected cases in 2013.3 However, case
numbers remained static despite improved control of the TB
epidemic and the estimated prevalence of HIV in new TB cases in
the Asia-Paciﬁc region increased to 6.3% in 2013.3
On the positive side, from 2004 to 2012 the Asia-Paciﬁc region
achieved signiﬁcant reductions in TB-related deaths among people
living with HIV, including major reductions in Cambodia (>50%)
and China (25–50%), and a moderate reduction in Vietnam
(<25%).33 However, ART coverage for people living with HIV
remains inadequate; six out of seven (86%) high TB/HIV burden
(>1% co-infection rate) countries reported less than 50% ART
coverage among co-infected people in 2012.34,35
4.2. TB disease proﬁle
Unlike other opportunistic infections, TB disproportionately
affects people living with HIV even before any signiﬁcant drop
in CD4+ T cell counts or clinical signs suggestive of HIV/AIDS
occur. Table 2 summarizes TB disease characteristics associated
with different levels of HIV-induced immune compromise.36–38
In TB endemic settings, TB is often the presenting disease
in people living with HIV. An optimal screening tool requires
high negative predictive value to reliably ‘rule out’ TB.39 Since
24–61% of TB/HIV co-infected patients present with sputum
smear-negative disease, routine sputum microscopy is not
adequate to rule out active TB in people living with HIV.40
Pragmatic active TB case ﬁnding requires regular symptomatic
screening (current cough, fever/night sweats, fatigue, or weight
loss),41 with additional testing of symptomatic patients to
exclude active TB.
Novel approaches such as the Xpert MTB/RIF assay (Cepheid
Inc., Sunnyvale, CA, USA) have increased sensitivity compared to
sputum smear microscopy. This assay is associated with a 35–45%
improvement in diagnostic sensitivity for people living with
HIV42,43 and has the advantage of detecting both TB and resistance
to rifampin in less than 2 h.44 For these reasons, the WHO have
endorsed Xpert MTB/RIF as a primary TB diagnostic test in
symptomatic people living with HIV.25,45 The availability of Xpert
MTB/RIF has increased throughout the Asia-Paciﬁc region, with
continued expansion in Cambodia, India, Indonesia, Myanmar, the
Philippines, and Vietnam as part of a UNITAID-funded project.46 In
the subgroup of severely immunocompromised patients (CD4
counts of less than 50–100 cells/ml) in whom it is most
problematic to rule out active TB with conﬁdence, use of the
urine lipoarabinomannan (LAM) assay combined with sputum
Xpert MTB/RIF enhances diagnostic sensitivity.47,48 The availabili-
ty of a single reliable point-of-care screening test remains a major
clinical need.
The majority of TB/HIV co-infected patients develop classic
pulmonary disease with ﬁbronodular and/or cavitary lesions on
chest radiograph.26 However, clinical disease manifestations are
largely dependent on the level of immunosuppression. More
severely immunocompromised individuals have a greater risk of
extrapulmonary and disseminated forms of TB (Table 2). Persons
with CD4 cell counts of <200 cells/ml are less likely to present with
cavitation and often have atypical features. Most patients with
advanced immunosuppression (<100 cells/ml) have extrapul-
monary and disseminated forms of TB,49 positive mycobacterial
blood cultures, and atypical chest radiography ﬁndings.50 Common
extrapulmonary sites include lymph nodes and pleura or
disseminated (miliary) disease; less commonly the pericardium,meninges/brain, or abdomen is also involved.51 Knowledge of the
epidemiological context and the vulnerability proﬁle of the
patient, and assiduous efforts to obtain appropriate specimens
for mycobacterial testing are essential to diagnose TB in people
living with HIV.52
Immune reconstitution inﬂammatory syndrome (IRIS) is
deﬁned as new or worsening symptoms and signs of TB within
4–8 weeks of ART initiation, despite improved virological control
and immunological recovery.39 The incidence of TB-IRIS in co-
infected patients ranges from 7% to 36%.35 In the Asia-Paciﬁc
region, the rates of TB-IRIS among co-infected patients with HIV
and TB who received ART during TB treatment were 26.2% in
Thailand53 and 8% in India.54 IRIS presentations include unmask-
ing of previously undiagnosed TB, paradoxical deterioration of
pre-existing TB lesions, or the appearance of new lesions after ART
initiation. Manifestations may include high fever, lymph node
enlargement, worsening respiratory symptoms and signs, cold
abscess formation, or worsening of central nervous system lesions
(tuberculoma and meningitis).35,55 The key predictor of IRIS is the
degree of HIV-induced immunosuppression (low CD4+ count) at
ART initiation,56 although a high viral load at the start of
treatment, rapidity of viral load decline, Mycobacterium tubercu-
losis antigen load, and genetic predisposition (HLA B-44) may also
inﬂuence risk.39
As in adults, TB is a leading cause of death in HIV-infected
children.57 Children living in HIV-affected households are at
increased risk of TB exposure and infection irrespective of their
own HIV status, with those who are HIV-infected being at increased
risk of developing TB disease progression.58,59 The clinical approach
to TB diagnosis is similar to adults with sputum smear-negative
disease, taking into account the likelihood of TB exposure, proof of M.
tuberculosis infection (tuberculin skin test induration of 5 mm, or a
positive M. tuberculosis interferon-gamma-release assay), clinical
features, and chest X-ray signs suggestive of TB, as well as
appropriate microbiological evaluation.59,60
4.3. TB infection control and prevention
The importance of infection control was put under the
spotlight with the massive hospital-acquired outbreak of exten-
sively drug-resistant tuberculosis (XDR-TB) that involved
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12 collaborative TB/HIV activities recommended by the WHO, the
three ‘I’s (isoniazid preventive therapy, intensiﬁed case ﬁnding,
and infection control) are regarded as core prevention strate-
gies.21,23 High infection control vigilance is required, since people
living with HIV are more susceptible to progress to disease
following primary or re-infection with M. tuberculosis than
immune-competent individuals, and are more likely to be
infectious themselves.
The risk of developing TB approaches 10–20% per annum
among HIV-infected immunocompromised patients living in TB
endemic areas.62 Early ART initiation and universal ART access
are key components in national strategies to reduce the risk of
HIV-associated TB across all CD4+ T-cell strata7. However, ART
access remains limited and highly variable across the Asia-Paciﬁc
region.63 Only Cambodia has more than 50% of all people living
with HIV currently on ART.64 Studies in Cambodia and South
Africa have indicated that early ART initiation reduces mortality
in TB patients, especially among those with low CD4+ T-cell
counts.65,66 Revised WHO guidelines recommend starting ART
as soon as possible and within the ﬁrst 8 weeks of TB treatment
initiation.23,25
4.4. Drug-resistant TB
The rise of drug-resistant TB threatens global TB control and
is a major public health concern.67 Outbreaks of TB and
multidrug-resistant (MDR)-TB within hospital settings have
been documented in diverse geographical settings.60,68 Although
MDR-TB appears not to cause infection or disease more readily
than drug-susceptible TB, delayed diagnosis, inadequate initial
treatment, and prolonged infectiousness contribute to increased
attack rates among contacts and high case-fatality among
patients.69 In 2013, the WHO estimated that there were
480 000 new cases of MDR-TB and approximately 210 000
deaths from MDR-TB globally.3 The Asia-Paciﬁc region includes
seven countries (India, China, Philippines, Indonesia, Myanmar,Table 3
Advantages and disadvantages of Mycobacterium tuberculosis strain typing methods us
Advantages 
IS6110 restriction fragment length polymorphism typing (RFLP)
 Well validated technique
 High discriminatory power in strains with multiple IS6110 insertion sites
 High stability (slow insertion rate)
Spoligotyping
 Rapid, reproducible, and affordable
 Easy to compare results between laboratories
 Does not require a viable culture and only a small amount of DNA is
needed
 Reliable method for determining strain relationships and assigning
phylogenetic lineages87–89
Mycobacterial interspersed repetitive unit analysis (MIRU)
 Rapid, reproducible, and cheaper than RFLP
 Easy to compare results between laboratories
 Does not require a viable culture and only a small amount of DNA
is needed
 Higher discriminatory power than spoligotyping; MIRU-24 comparable
to RFLP90
Whole genome sequencing (WGS)
 Bench-top sequencing instruments becoming more affordable
 Ultimate discriminatory power; complete sequencing data provide a
‘future-proof’ output
 Unprecedented levels of evolutionary insight
 Can infer the likely direction of transmissionBangladesh, and Vietnam) among the 27 high-burden MDR-TB
countries that accounted for more than 50% of estimated MDR-
TB cases occurring worldwide in 2013.3,70 India and China, the
two countries estimated to have the largest numbers of patients
with MDR-TB, strongly inﬂuence the overall ﬁgures for the Asia-
Paciﬁc region.3 The worldwide emergence of XDR-TB3 and
recent reports of ‘totally drug-resistant TB’ from Iran and
India71,72 pose a major threat to TB control and public health in
general. In particular, the overlap of TB/HIV co-infection with
drug-resistant TB presents a tremendous challenge and threa-
tens recent progress in reducing the mortality associated with
both diseases. Ensuring optimal treatment of all drug-suscepti-
ble TB cases, the expansion of early and rapid MDR-TB case
detection, and access to adequate MDR-TB treatment must be
prioritized.
4.5. TB recurrence
Besides increasing the risk of progression from latent TB
infection to active disease, HIV also increases the rate of TB
recurrence.73 TB recurrence occurs when patients who were
previously treated for TB develop a new disease episode, due to
either relapse (recurrence of the old infection) or re-infection
(infection with a new strain).74 Relapse and re-infection cannot be
differentiated by clinical features; this requires comparison of the
M. tuberculosis strains isolated during the initial and subsequent TB
episodes by molecular subtyping.75 The prevalence of TB recur-
rence is greater in patients previously treated for TB than the
prevalence of new TB episodes in the general population.76 It is a
particular problem in HIV-infected people living in TB endemic
areas, in whom recurrence rates of up to 24.4% have been reported
within 2 years of successful TB treatment completion.13 In
countries with a low TB incidence, recurrence seems to be
attributable to relapse in most cases,77 but exogenous re-infection
seems to be the main driver in TB endemic areas. Molecular studies
suggest that 88% of TB recurrences among people living with HIV in
India are due to re-infection.78–81ed to differentiate re-infection from relapse during TB recurrence
Disadvantages
 Requires a viable culture and large amount of DNA
 Labour-intensive and time-consuming
 High level of technical expertise required
 Reproducibility and comparability problematic
 Supplementary methods necessary in low copy number strains, which have
been prevalent in South East Asia82
 Relatively poor discriminatory power
 Inability to differentiate some common phylogenetic lineages, Beijing in
particular88
 Not always able to obtain complete MIRU proﬁle
 Stability/mutation rate unclear
 Limited capacity to distinguish relapse from re-infection in outbreak
situations
 Beijing lineage isolates requires additional analysis (i.e., supplementary loci)
for enhanced discriminatory power85
 Expensive and slow turnaround times (prices and turnaround times dropping
constantly)
 High level of technical expertise
 Complex quality control requirements to ensure harmonization of results
 Complicated bioinformatics and specialist software required91
*Factors associated with  relapse  or re-in fecti on risk  
**I n the general  pop ulati on and in specific  sub- pop ulati ons 
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TREATMENT
RESPONSE
*Relapse 
1) Treat ment re gime n 
    - Inadeq uate drug  cho ice 
    - Substandar d drug quality 
    - Unrecognized  drug resistance 
2) Treat ment adhere nce
    - Drug  stoc k outs 
    - Poor  compliance 
3) Drug  pharmacod ynamics and 
pharmacokinetics
     - Poor  drug penet rati on  
     - Va riable pharmacokinetic s  
INDIVIDUAL
VULNERABILITY 
*Relapse or  re-infection 
1) Immun e co mpromi se 
    - HIV  infection (CD4 count ) 
    - Malnut ritio n 
    - Diab ete s  
    - Alcohol/substance  abuse 
    - Ext remes of  ag e 
2) Reduce d local defe nces
    - Cigarette smoking 
    - Air  pollution (in-  and  outdoo r) 
    - Sili coses 
    - Chronic lu ng disease 
TB RECURRENCE RISK 
*Relapse or  re-infectio n
REPEAT EXPOSURE
*Re-infecti on
1) Epidemi c control   
- TB  prev alence**   
2) Infection  control***   
  - Cli nics, hosp ital s 
  - Publi c transport  
  - Pla ces of  social iza tio n 
  - Prison   
3) TB  in  close  contacts   
  - Family memb ers 
  - Soci al, work  rel ation s 
  - Li ving  conditions,  ove rcrowding 
Figure 2. Determinants of TB recurrence risk due to relapse and/or re-infection.
Table 4
Factors associated with TB recurrence in HIV-infected patients; differentiating
relapse and re-infection
Type of recurrence Risk factor
Not speciﬁed Poor treatment adherence/drug quality101
Weak treatment regimen93
Age (>30 years)94,99
CD4 cell count (<200/mm3)95,96
Low Hb (<12 g/dl); marker of more advanced
disease94,99
Poor weight gain on treatment (<3 kg after
2 months); marker of poor treatment response94,99
Relapse Drug resistance98
Degree of immune compromise (CD4 cell
count)97,105
Poor treatment adherence83,99–101
Beijing genotype106
Thiacetazone (T)-containing regimen93
Re-infection High levels of TB exposure within the household
family, community, social behaviour linked
Poor infection control measures at health
facilities35,101,105,107
HIV-1 infection79
Hb, haemoglobin.
Q.M. Trinh et al. / International Journal of Infectious Diseases 32 (2015) 170–178 175It is unfortunate that the WHO continues to use the term
‘relapse’ to describe any TB recurrence during programmatic
assessment. This is confusing since it fails to differentiate relapse
(i.e., failure of clinical management) from re-infection (i.e.,
failure of public health interventions). This differentiation has
important clinical and public health implications. In the case of
TB relapse, reasons for treatment failure should be scrutinized
carefully. If re-infection is documented, potential sources of
TB exposure should be considered. In TB treatment trials, it is
important to differentiate relapse from re-infection, since only
the former represents treatment failure.82
Numerous attempts have been made to differentiate re-
infection from relapse using molecular strain typing techniques.
One of the earliest and most widely applied molecular typing
methods is IS6110-based restriction fragment length polymor-
phism (RFLP) typing.83 However, mycobacterial interspersed
repetitive unit–variable number of tandem repeats (MIRU-VNTR)
typing using 24 loci is currently the most reproducible and widely
used method.84 For rapid and reliable genotyping analysis, a
combination of spoligotyping and 24-locus MIRU-VNTR is often
employed. However, whole genome sequencing (WGS) offers the
highest resolution possible and may soon become the new
‘reference standard’, given the rapid development of this
technology.85 Traditional methods are unable to distinguish
relapse from re-infection within an outbreak situation, and their
ability to differentiate highly monomorphic phylogenetic
lineages, such as Beijing which dominates in large parts of the
Asia-Paciﬁc region, remains poor. WGS analysis has been used to
differentiate relapse from re-infection in cases where the
spoligotyping/MIRU-VNTR proﬁle was not informative.86
Table 3 summarizes the different genotyping techniques that
are available, as well as the advantages and limitations associated
with each method.87–91
Rates of TB recurrence in people living with HIV vary
considerably depending on the level of care provided and the
transmission/epidemic control achieved in a particular area. In
South India, 88% of recurrent TB among HIV-infected patients was
attributed to exogenous re-infection;78 this percentage was
reported to be 29% in Spain92 and only 7% in North America.77Figure 2 provides a comprehensive overview of factors associated
with the risk of TB recurrence. Table 4 describes speciﬁc risk
factors associated with relapse and re-infection.93–97 Drug-
resistant TB is an important consideration in patients who
experience TB treatment failure or true disease relapse,98 as is
treatment adherence and the quality of care received.99–101 TB
recurrence due to re-infection increases with higher infection
pressure and longer duration of follow-up.76,77,102,103 A recent
study from Uganda reported high TB recurrence rates both in HIV-
infected and un-infected individuals.100 The overall TB recurrence
rate was 8.4/100 person-years during the 2-year study period:
9.4 and 6.7/100 person-years in HIV-infected and un-infected
individuals, respectively.100 In HIV-infected patients, the average
time to TB relapse was 8.1 months and to TB re-infection
20.1 months.104
Q.M. Trinh et al. / International Journal of Infectious Diseases 32 (2015) 170–1781765. Conclusions
A slowly emerging TB/HIV co-infection epidemic in the Asia-
Paciﬁc region is suggested by increasing proportions of TB/HIV
co-infected patients, despite reductions in TB case numbers. The
double burden of TB and HIV, together with increasing rates
of MDR-TB, complicates the management of both diseases and
emphasizes the need for strong coordination between national
TB and HIV/AIDS control programmes. It is important to
understand the factors contributing to TB recurrence, since
high rates of TB relapse demand renewed efforts to improve
individual patient care, while high rates of re-infection demand
improved infection and epidemic control measures. Concerted
regional action is required to limit expansion of the TB/HIV co-
infection epidemic and to contain the spread of drug-resistant
TB in the Asia-Paciﬁc region.41
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